tradingkey.logo
tradingkey.logo
Search

Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism

ReutersSep 2, 2025 12:25 PM
facebooktwitterlinkedin

Rezolute Inc RZLT.O:

  • REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM

  • REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026 - SEC FILING

  • REZOLUTE INC: FDA ALSO CONFIRMED THAT REZOLUTE S PIVOTAL SUNRIZE TRIAL IN CONGENITAL HI, WHICH IS ON TRACK TO REPORT TOPLINE RESULTS IN DECEMBER 2025

Source text: [ID:n0001104659-25-085892]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI